Figure 1.

Responses to revumenib in KMT2A-rearranged AML and ALL cells. (A) Cell viability in response to increasing concentrations of revumenib as assessed by 4-day MTT assays in KMT2A-rearranged (n = 6) and wildtype KMT2A (n = 3) AML cell line models. The dashed line shows the 50% viability threshold. Experiments were performed in technical triplicates and data consisted of three biological replicates. (B) IC₅₀-values (i.e., the inhibitory concentration to 50% of the leukemic cells) for revumenib as determined by nonlinear regression in KMT2A-rearranged and wildtype KMT2A AML cell lines, statistically evaluated by an unpaired two-tailed t-test, with ns showing no significant differences. (C) Cell viability in response to increasing concentrations of revumenib using 4-day MTT assays in ex vivo pediatric KMT2A-rearranged AML patient samples obtained from patient-derived xenograft mouse models (n = 3). The dashed line shows the 50% viability threshold. Experiments were performed in technical triplicates. (D) Cell viability in response to increasing concentrations of revumenib as assessed by 4-day MTT assays in KMT2A-rearranged ALL cell line models (n = 5) and wildtype KMT2A ALL cell lines (n = 2). The dashed line shows the 50% viability threshold. Experiments were performed in technical triplicates and data consisted of three biological replicates. (E) IC₅₀-values for revumenib as determined by nonlinear regression in KMT2A-rearranged and wildtype KMT2A ALL cell lines, statistically evaluated by an unpaired two-tailed t-test; * p < 0.05 (F) Cell viability in response to increasing concentrations of revumenib using 4-day MTT assays in ex vivo pediatric KMT2A-rearranged ALL patient samples (n = 5). The dashed line shows the 50% viability threshold Experiments were performed in technical triplicates.